NanoViricides pairs a potentially mutation-resistant, oral antiviral platform and a $200 million PRV opportunity with no revenue, a going-concern warning, and substantial clinical and dilution risk.
Overview
NanoViricides (NYSE American: NNVC) is a clinical-stage antiviral company with no commercial revenue: FY25 and FY26 revenue were both **$0**. Its core asset, oral/systemic NV-387, uses polymeric micelles that mimic host-cell receptors to bind and destroy viruses; after Phase Ia safety testing without reported adverse events or dropouts, it is in Phase II trials for Mpox and Ebola in the DRC. The pipeline also includes Measles, respiratory viruses, HerpeCide, HIVCide, and a remdesivir delivery combination. The proposed edge is broad-spectrum activity and a higher barrier to viral resistance, supported by an owned cGMP facility and exclusive commercial licenses, though clinical efficacy and commercial advantage remain unproven. FY26 net loss narrowed to $8.219 million from $9.467 million, but cash was only $2.79 million against $7.7 million annual operating burn; the auditor raised substantial doubt about going concern. A July 2026 offering added $3.5 million net but increased dilution. Shares traded around $1.30–$1.35, while cited analyst targets average $6.00–$6.12. The report’s probability-weighted five-year target is **$6.52**, driven by Phase II progress and potential Measles PRV monetization, but its 35% low-case probability produces a $0.14 outcome. This is speculative clinical optionality, not a proven earnings or revenue compounder.